410 related articles for article (PubMed ID: 26851830)
1. Treatment of recalcitrant bullous pemphigoid (BP) with a novel protocol: A retrospective study with a 6-year follow-up.
Ahmed AR; Shetty S; Kaveri S; Spigelman ZS
J Am Acad Dermatol; 2016 Apr; 74(4):700-8.e3. PubMed ID: 26851830
[TBL] [Abstract][Full Text] [Related]
2. Positive clinical outcome in a patient with recalcitrant bullous pemphigoid treated with rituximab and intravenous immunoglobulin.
Nguyen T; Ahmed AR
Clin Exp Dermatol; 2017 Jul; 42(5):516-519. PubMed ID: 28508388
[TBL] [Abstract][Full Text] [Related]
3. Rituximab therapy in patients with bullous pemphigoid: A retrospective study of 20 patients.
Polansky M; Eisenstadt R; DeGrazia T; Zhao X; Liu Y; Feldman R
J Am Acad Dermatol; 2019 Jul; 81(1):179-186. PubMed ID: 30923002
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases.
Lamberts A; Euverman HI; Terra JB; Jonkman MF; Horváth B
Front Immunol; 2018; 9():248. PubMed ID: 29520266
[TBL] [Abstract][Full Text] [Related]
5. Bullous pemphigoid treated with intravenous immunoglobulin.
Tuchinda P; Ritchie S; Gaspari AA
Cutis; 2014 May; 93(5):264-8. PubMed ID: 24897141
[TBL] [Abstract][Full Text] [Related]
6. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
[TBL] [Abstract][Full Text] [Related]
7. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report.
Foster CS; Chang PY; Ahmed AR
Ophthalmology; 2010 May; 117(5):861-9. PubMed ID: 20045562
[TBL] [Abstract][Full Text] [Related]
8. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP).
Maley A; Warren M; Haberman I; Swerlick R; Kharod-Dholakia B; Feldman R
J Am Acad Dermatol; 2016 May; 74(5):835-40. PubMed ID: 26936298
[TBL] [Abstract][Full Text] [Related]
9. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events.
Seidling V; Hoffmann JH; Enk AH; Hadaschik EN
Acta Derm Venereol; 2013 May; 93(3):346-9. PubMed ID: 23073990
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.
Ahmed AR
J Am Acad Dermatol; 2001 Dec; 45(6):825-35. PubMed ID: 11712025
[TBL] [Abstract][Full Text] [Related]
11. Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study.
Tsai YJ; Cho YT; Chu CY
Am J Clin Dermatol; 2022 Jul; 23(4):571-585. PubMed ID: 35579853
[TBL] [Abstract][Full Text] [Related]
12. Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.
Daoud YJ; Amin KG
Int Immunopharmacol; 2006 Apr; 6(4):600-6. PubMed ID: 16504922
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of rituximab in a case of refractory bullous pemphigoid].
Reguiaï Z; Tchen T; Perceau G; Bernard P
Ann Dermatol Venereol; 2009 May; 136(5):431-4. PubMed ID: 19442800
[TBL] [Abstract][Full Text] [Related]
14. Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature.
Kremer N; Snast I; Cohen ES; Hodak E; Mimouni D; Lapidoth M; Mazor S; Levi A
Am J Clin Dermatol; 2019 Apr; 20(2):209-216. PubMed ID: 30421306
[TBL] [Abstract][Full Text] [Related]
15. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
16. Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature.
Shetty S; Ahmed AR
J Drugs Dermatol; 2013 Jun; 12(6):672-7. PubMed ID: 23839185
[TBL] [Abstract][Full Text] [Related]
17. Combined Use of Rituximab and Intravenous Immunoglobulin for Severe Autoimmune Cicatricial Conjunctivitis-An Interventional Case Series.
Steger B; Madhusudan S; Kaye SB; Stylianides A; Romano V; Maqsood SE; Harper J; Ahmad S
Cornea; 2016 Dec; 35(12):1611-1614. PubMed ID: 27661067
[TBL] [Abstract][Full Text] [Related]
18. Rituximab Therapy for Mucous Membrane Pemphigoid: A Retrospective Monocentric Study With Long-Term Follow-Up in 109 Patients.
Bohelay G; Alexandre M; Le Roux-Villet C; Sitbon I; Doan S; Soued I; Shourick J; Rousset L; Mellottee B; Heller M; Lièvre N; Zumelzu C; Morin F; Grootenboer-Mignot S; Gabison E; Caux F; Prost-Squarcioni C; Musette P
Front Immunol; 2022; 13():915205. PubMed ID: 35844526
[TBL] [Abstract][Full Text] [Related]
19. Postvaccinal, corticosteroid-resistant bullous pemphigoid in infancy: treatment with intravenous immunoglobulin.
Ister M; Pouessel G; Ythier H; Catteau B; Carpentier O
Pediatr Dermatol; 2014; 31(4):e94-5. PubMed ID: 24916151
[TBL] [Abstract][Full Text] [Related]
20. Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study.
You C; Lamba N; Lasave AF; Ma L; Diaz MH; Foster CS
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1221-1228. PubMed ID: 28154932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
